DXC DXC
Company Profile ↓Company Overview
DXC (DXC) is a publicly traded company listed on with a market capitalization of $1.91B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $12.64B (-1.8% YoY); net profit $18.00M.
- Trailing 12 Months Year-on-year growth — revenue -1.8%, earnings -95.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.9%, profit CAGR -23.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.93% |
| 1 Year: | -1.76% |
Compounded Profit Growth
| 5 Years: | -23.16% |
| 1 Year: | -95.37% |
Stock Price Performance
| 1 Year: | -16.64% |
| 6 Months: | -17.63% |
| 3 Months: | -6.24% |
| 1 Month: | +9.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)63.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 111.2.
- Earnings shrank at -23.2% CAGR over 5 years.
- Trading 27.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Jan 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Jun 2018 | Sep 2018 | Dec 2018 | Jun 2019 | Sep 2019 | Dec 2019 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.47B | 1.93B | 1.87B | 1.92B | 4.15B | 5.24B | 5.45B | 5.46B | 5.28B | 5.01B | 5.18B | 4.89B | 4.85B | 5.02B | 4.50B | 4.55B | 4.29B | 4.14B | 4.03B | 4.09B | 3.71B | 3.57B | 3.57B | 3.45B | 3.44B | 3.40B | 3.24B | 3.24B | 3.23B | 3.16B | 3.16B | 3.19B | 3.00B |
| Operating Income | -174.00M | 106.00M | 120.00M | 176.00M | -30.00M | 570.00M | 740.00M | 797.00M | 803.00M | 799.00M | 840.00M | 652.00M | 529.00M | 528.00M | 190.00M | 283.00M | 300.00M | 332.00M | 346.00M | 355.00M | 259.00M | 269.00M | 309.00M | 224.00M | 251.00M | 256.00M | 224.00M | 279.00M | 286.00M | 216.00M | 254.00M | 263.00M | 150.00M |
| Net Income | -178.00M | -21.00M | 15.00M | 31.00M | -37.00M | 159.00M | 256.00M | 776.00M | 259.00M | 262.00M | 462.00M | 163.00M | -2.12B | 82.00M | -205.00M | -244.00M | 1.10B | 278.00M | -188.00M | 98.00M | 102.00M | 27.00M | 59.00M | 36.00M | 99.00M | 156.00M | 26.00M | 42.00M | 57.00M | 16.00M | 36.00M | 107.00M | 122.00M |
| Diluted EPS | - | -0.15 | 0.10 | 0.21 | - | 0.55 | 0.88 | 2.68 | 0.90 | 0.92 | 1.66 | 0.61 | -8.19 | 0.32 | -0.81 | -0.96 | 4.29 | 1.07 | -0.74 | 0.38 | 0.43 | 0.12 | 0.25 | 0.17 | 0.49 | 0.81 | 0.14 | 0.23 | 0.31 | 0.09 | 0.20 | 0.61 | 0.73 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.11B | 7.61B | 21.73B | 20.75B | 19.58B | 17.73B | 16.27B | 14.43B | 13.67B | 12.87B | 12.64B |
| Operating Income | 405.00M | 618.00M | 2.99B | 3.27B | 2.06B | 1.10B | 1.38B | 1.14B | 1.01B | 1.02B | 970.00M |
| Net Income | 251.00M | -123.00M | 1.75B | 1.26B | -5.37B | -149.00M | 718.00M | -568.00M | 91.00M | 389.00M | 18.00M |
| Diluted EPS | 1.78 | -0.88 | 6.04 | 4.47 | -20.76 | -0.59 | 2.81 | -2.48 | 0.46 | 2.10 | 0.10 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2015 | Apr 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.74B | 8.66B | 33.92B | 29.57B | 26.01B | 22.04B | - | 15.85B | 13.87B | 13.21B | 12.89B |
| Current Assets | - | - | - | - | - | - | - | - | 6.12B | 5.13B | 5.36B | 5.36B |
| Cash & Equivalents | - | - | 1.26B | 2.59B | 2.90B | 3.68B | 2.97B | - | 1.86B | 1.22B | 1.80B | 1.74B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 1.53B | 1.43B | 1.33B | 1.24B |
| Total Liabilities | - | - | 6.50B | 20.08B | 17.85B | 20.88B | 16.73B | - | 12.03B | 10.80B | 9.71B | 9.68B |
| Current Liabilities | - | - | 2.95B | 9.85B | 9.45B | 7.89B | 8.15B | - | 5.19B | 4.39B | 4.41B | 3.94B |
| Long Term Debt | - | - | 2.23B | 6.09B | 5.47B | 8.67B | 4.34B | - | 3.61B | 3.58B | 2.84B | 2.95B |
| Total Debt | - | - | - | - | - | - | - | - | 5.37B | 4.87B | 4.55B | 4.25B |
| Total Equity | 2.96B | 2.03B | 1.89B | 13.49B | 11.40B | 4.79B | 4.97B | - | 3.50B | 2.81B | 3.23B | 2.94B |
| Shares Outstanding | - | - | - | - | - | - | - | - | 218.06M | 183.43M | 186.86M | 171.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 802.00M | 619.00M | 2.57B | 1.78B | 2.35B | 124.00M | 1.50B | 1.42B | 1.36B | 1.40B | 1.25B |
| Investing Cash Flow | -1.18B | -565.00M | 719.00M | 69.00M | -2.14B | 4.67B | -60.00M | -635.00M | -491.00M | -512.00M | -484.00M |
| Financing Cash Flow | -485.00M | 93.00M | -1.89B | -1.66B | 657.00M | -5.48B | -1.82B | -1.51B | -1.49B | -317.00M | -776.00M |
| Capital Expenditure | -356.00M | -246.00M | -224.00M | -297.00M | -350.00M | -261.00M | -254.00M | -267.00M | -182.00M | -248.00M | -212.00M |
| Free Cash Flow | 446.00M | 373.00M | 2.34B | 1.49B | 2.00B | -137.00M | 1.25B | 1.15B | 1.18B | 1.15B | 1.04B |
| Share Buybacks | - | - | - | - | - | - | 628.00M | 669.00M | 898.00M | 14.00M | 249.00M |
| Dividends Paid | 430.00M | 78.00M | 174.00M | 210.00M | 214.00M | 53.00M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Apr 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 5.7% | 8.1% | 13.8% | 15.8% | 10.5% | 6.2% | 8.5% | 7.9% | 7.4% | 7.9% | 7.7% |
| Net Margin % | 3.5% | -1.6% | 8.1% | 6.1% | -27.4% | -0.8% | 4.4% | -3.9% | 0.7% | 3.0% | 0.1% |
| ROE % | 12.4% | -6.5% | 13.0% | 11.0% | -112.2% | -3.0% | - | -16.2% | 3.2% | 12.0% | 0.6% |
| ROCE % | - | 10.8% | 12.4% | 16.2% | 11.4% | 7.9% | - | 10.7% | 10.6% | 11.6% | 10.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DXC
DXC Appoints Lisa Beaudoin as Chief Product Officer to Accelerate Product-Led Growth
DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced the appointment of Lisa Beaudoin as Chief Product Officer. In this role, Beaudoin will lead a newly unified product development organization…
The Hidden Turbulence Priced Into Accenture Stock
Beneath its blue-chip exterior, the market is pricing a remarkably wide range of outcomes for this consulting giant, and shareholders are carrying that full exposure.
DXC (DXC) Q1 2027 Earnings Call Transcript
AI transition strategy gains traction as infrastructure segment faces near-term headwinds.
DXC Q2 Deep Dive: AI Initiatives and Leadership Changes Shape Strategic Outlook
IT services provider DXC Technology (NYSE:DXC) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 5.1% year on year to $3.00 billion. On the other hand, next quarter’s revenue guidance of $2.99 billion was less impressiv…
DXC Technology (DXC) Teams Up With ElevenLabs To Push Voice AI Into Enterprise Work
DXC Technology (NYSE:DXC) has entered a new partnership with ElevenLabs to roll out advanced voice AI across its operations and client solutions. The collaboration focuses on co-innovation, expanded product offerings, and a shared go-to-mar…
DXC Technology (DXC) Earnings And Guidance Put Fair Value Back In Focus
DXC Technology (DXC) has come into focus after reporting first quarter fiscal 2027 results, with revenue of US$2.999b and net income of US$122m, followed by updated guidance and fresh leadership changes. See our latest analysis for DXC Tech…
DXC — Frequently Asked Questions
What is the current share price of DXC?
As of 2026-08-05 17:25 PDT, DXC trades at $11.12 on NASDAQ/NYSE. Its 52-week range is $8.22 to $15.43.
What is the market capitalisation of DXC?
DXC has a market capitalisation of $1.91B on NASDAQ/NYSE.
What is the P/E ratio of DXC?
DXC trades at a trailing price-to-earnings (P/E) ratio of 111.20. Its price-to-book (P/B) ratio is 0.65.
What is the return on equity (ROE) of DXC?
DXC has a return on equity (ROE) of 0.61%. Its return on capital employed (ROCE) is 10.84%.
Is DXC a good stock to buy?
This page provides a data-driven analysis of DXC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.